Disclosed in certain embodiments is a solid oral dosage form comprising a heat-labile gelling agent; a thermal stabilizer; and a drug susceptible to abuse.
대표청구항▼
1. A solid oral dosage form comprising a a heat-labile gelling agent;a thermal stabilizer;a drug susceptible to abuse; anda pH-modifying agent. 2. The solid oral dosage form of claim 1, wherein the heat-labile gelling agent is a polymer. 3. The solid oral dosage form of claim 2, wherein the polymer
1. A solid oral dosage form comprising a a heat-labile gelling agent;a thermal stabilizer;a drug susceptible to abuse; anda pH-modifying agent. 2. The solid oral dosage form of claim 1, wherein the heat-labile gelling agent is a polymer. 3. The solid oral dosage form of claim 2, wherein the polymer is a polysaccharide. 4. The solid oral dosage form of claim 3, wherein the polysaccharide is a microbial polysaccharide. 5. The solid oral dosage form of claim 4, wherein the microbial polysaccharide is xanthan gum. 6. The solid oral dosage form of claim 1, wherein the thermal stabilizer is a gelling agent different than the heat-labile gelling agent. 7. The solid oral dosage form of claim 6, wherein the thermal stabilizer gelling agent is a polymer. 8. The solid oral dosage form of claim 7, wherein the thermal stabilizer gelling agent polymer is an anionic polymer in a neutral pH aqueous solution. 9. The solid oral dosage form of claim 8, wherein the anionic polymer is a polyacrylic acid. 10. The solid oral dosage form of claim 9, wherein the polymer is carbomer homopolymer. 11. The solid oral dosage form of claim 10, wherein the heat-labile gelling agent is a polysaccharide. 12. The solid oral dosage form of claim 11, wherein the polysaccharide is a microbial polysaccharide. 13. The solid oral dosage form of claim 1, wherein the heat-labile gelling agent is xanthan gum and the thermal stabilizer is carbomer homopolymer. 14. The solid oral dosage form of claim 1, wherein the pH-modifying agent provides a pH of between about 5.5 and 8.5 to a viscous solution obtained when the dosage form is crushed and mixed with 5 mL of distilled water. 15. The solid oral dosage form of claim 14, wherein the pH-modifying agent provides a pH of between about 6 and 8. 16. The solid oral dosage form of claim 15, wherein the pH-modifying agent provides a pH of between about 6.5 and 7.5. 17. The solid oral dosage form of claim 1, wherein the pH-modifying agent is sodium bicarbonate. 18. The solid oral dosage form of claim 1, further comprising a disintegrant. 19. The solid oral dosage form of claim 18, wherein the disintegrant is selected from the group consisting of polyvinylpyrrolidone, sodium starch glycolate, crosscarmellose sodium and a mixture thereof. 20. The solid oral dosage form of claim 1, further comprising a filler. 21. The solid oral dosage form of claim 20, wherein the filler is selected from the group consisting of lactose, dextrose, mannitol, microcrystalline cellulose and a mixture thereof. 22. The solid oral dosage form of claim 1, comprising the heat-labile gelling agent in an amount from about 0.25% to about 75% (w/w) of the dosage form. 23. The solid oral dosage form of claim 1, comprising the thermal stabilizer in an amount from about 0.25% to about 90% (w/w) of the dosage form. 24. The solid oral dosage form of claim 1, wherein the ratio of the heat-labile gelling agent to the thermal stabilizer is from about 1:10 to about 10:1 (w/w). 25. The solid oral dosage form of claim 1, comprising the pH-modifying agent in an amount from about 0.1% to about 25% (w/w) of the dosage form. 26. The solid oral dosage form of claim 18, comprising the disintegrant in an amount from about 1% to about 25% (w/w) of the dosage form. 27. The solid oral dosage form of claim 20, comprising the filler in an amount from about 5% to about 95% (w/w) of the dosage form. 28. The solid oral dosage form of claim 1, wherein the ratio of the drug to the heatlabile gelling agent is from about 1:40 to about 40:1 (w/w). 29. The solid oral dosage form of claim 1, further comprising an aversive agent. 30. The solid oral dosage form of claim 29, wherein the aversive agent is selected from the group consisting of emetics, antagonists, bittering agents, irritants and mixtures thereof. 31. The solid oral dosage form of claim 1, wherein the drug is selected from the group consisting of opioid agonists, tranquilizers, CNS depressants, CNS stimulants, sedative hypnotics, and mixtures thereof. 32. The solid oral dosage form of claim 1, wherein the drug is an opioid agonist. 33. The solid oral dosage form of claim 32, wherein the opioid agonist is selected from the group consisting of codeine, morphine, oxycodone, oxymorphone, hydrocodone, hydromorphone, pharmaceutically acceptable salts thereof, and mixtures thereof. 34. The solid oral dosage form of claim 33, wherein the opioid agonist is oxycodone or a pharmaceutically acceptable salt thereof. 35. The solid oral dosage form of claim 34, comprising from about 5 mg to about 30 mg oxycodone or a pharmaceutically acceptable salt thereof. 36. The solid oral dosage form of claim 1, wherein the viscosity of the dosage form mixed with from about 0.5 to about 10 ml of distilled water prevents the drug from being systemically absorbed, or reduces the ability of the drug to be systemically absorbed, when administered by the parenteral or nasal route. 37. The solid oral dosage form of claim 1, wherein the viscosity of the solid oral dosage form after crushing and mixing with from about 0.5 to about 10 ml of distilled water prevents the drug from being systemically absorbed, or reduces the ability of the drug to be systemically absorbed, when administered by the parenteral or nasal route. 38. The solid oral dosage form of claim 36, wherein the viscosity after mixing with from about 0.5 to about 10 ml of distilled water is at least about 10 cP. 39. The solid oral dosage form of claim 36, wherein the viscosity after mixing with from about 0.5 to about 10 ml of distilled water is from about 50 cP to about 1,000 cP. 40. The solid oral dosage form of claim 36, wherein the viscosity after mixing with from about 0.5 to about 10 ml of distilled water is from about 100 cP to about 5,000 cP. 41. The solid oral dosage form of claim 1, which provides an immediate release of the drug. 42. The solid oral dosage form of claim 1, which provides a controlled release of the drug. 43. The solid oral dosage form of claim 41, wherein the dosage form releases at least about 85% of the drug within 45 minutes as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml SGF at 37° C. 44. The solid oral dosage form of claim 42, which provides a dissolution release rate in-vitro of the drug, when measured by the USP Basket Method at 100 rpm in 700 ml Simulated Gastric Fluid (SGF) without enzymes at 37° C. of at least about 15% by weight of the drug released at 1 hour and thereafter switching to 900 ml with Phosphate Buffer at a pH of 7.5 at 37° C., of from about 25% to about 65% by weight of the drug released at 2 hours, from about 45% to about 85% by weight of the drug released at 4 hours, and at least about 60% by weight of the drug released at 8 hours. 45. The solid oral dosage form of claim 1, wherein the recovery of the drug is less than about 10% based on a syringability test whereby the dosage form is crushed and mixed with 5 mL solvent and the resultant solution is aspired with a 27 gauge needle. 46. A solid oral dosage form comprising: a heat-labile gelling agent comprising xanthan gum;a thermal stabilizer comprising carbomer homopolymer;an opioid analgesic; anda pH modifying agent comprising sodium bicarbonate;wherein the dosage form releases at least about 85% of the drug within 45 minutes as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml SGF at 37° C. 47. A solid oral dosage form comprising: a heat-labile gelling agent comprising xanthan gum;a thermal stabilizer comprising carbomer homopolymer;an opioid analgesic comprising oxycodone, hydrocodone, a pharmaceutically acceptable salt thereof or mixtures thereof; anda pH modifying agent comprising sodium bicarbonate to provide a pH of between about 5.5 and 8.5 to a viscous solution obtained when the dosage form is crushed and mixed with 5 mL of distilled water;wherein the dosage form releases at least about 85% of the drug within 45 minutes as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml SGF at 37° C. 48. The solid oral dosage form of claim 46, further comprising an irritant. 49. The solid oral dosage form of claim 48, wherein the irritant comprises sodium lauryl sulfate. 50. The solid oral dosage form of claim 47, further comprising an irritant. 51. The solid oral dosage form of claim 50, wherein the irritant comprises sodium lauryl sulfate. 52. The solid oral dosage form of claim 46, wherein the recovery of the drug is less than about 10% based on a syringability test whereby the dosage form is crushed and mixed with 5 mL solvent and the resultant solution is aspired with a 27 gauge needle. 53. The solid oral dosage form of claim 47, wherein the recovery of the drug is less than about 10% based on a syringability test whereby the dosage form is crushed and mixed with 5 mL solvent and the resultant solution is aspired with a 27 gauge needle. 54. A solid oral dosage form comprising: a heat-labile gelling agent;a thermal stabilizer; anda drug susceptible to abuse;wherein the recovery of the drug is less than about 10% based on a syringability test whereby the dosage form is crushed and mixed with 5 mL solvent and the resultant solution is aspired with a 27 gauge needle.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (174)
Khanna Ish K. (Vernon Hills IL) Weier Richard M. (Lake Bluff IL) Collins Paul W. (Deerfield IL) Yu Yi (Skokie IL) Xu Xiangdong (Evanston IL) Partis Richard A. (Evanston IL) Koszyk Francis J. (Prospec, 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation.
Black Cameron (Pointe Claire CAX) Mancini Joseph A. (St. Leonard CAX) Lau Cheuk K. (Ile Bizard CAX) Prasit Petpiboon (Kirkland CAX) Vickers Philip J. (Pierrefonds CAX 4), 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents.
Hirsh,Jane; Kibanov,Alexander M.; Swager,Timothy M.; Buchwald,Stephen L.; Lo,Whe Yong; Fleming,Alison B.; Rariy,Roman V., Abuse-deterrent pharmaceutical compositions of opiods and other drugs.
Black W. Cameron (Pointe-Claire CAX) Li Chun-Sing (Dollard Des Ormeaux CAX) Guay Daniel (Notre Dame de L\lle Perrot CAX) Prasit Petpiboon (Kirkland CAX) Roy Patrick (Dollard Des Ormeaux CAX), Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) McGinity James (Austin TX) Bodmeier Roland (Austin TX), Aqueous dispersions of zein and preparation thereof.
Gauthier Jacques Y. (Laval CAX) Lau Cheuk K. (Ile Bizard CAX) LeBlanc Yves (Kirkland CAX) Li Chun-Sing (Dollard des Ormeaux CAX) Roy Patrick (Dollard des Ormeaux CAX) Therien Michel (Laval CAX) Wang , Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents.
Kuczynski Anthony L. ; Childers Jerry D. ; Barclay Glen E. ; Rodriguez Susan ; Merrill Sonya, Composition and dosage form comprising opioid antagonist.
Blumberg Peter M. (Frederick MD), Composition of resiniferatoxin and analogues thereof to cause sensory afferent C-Fiber and thermoregulatory desensitizat.
Drust Eugene G. (Norwich NY) Kasting Gerald B. (Wyoming OH) Smith Ronald L. (West Chester OH) Szkutak Joan B. (West Chester OH), Compositions for the transdermal delivery of pharmaceutical actives.
Oshlack Benjamin (New York NY) McGinity James (Austin TX) Chasin Mark (Manalapan NJ) Bodmeier Roland (Austin TX), Controlled release coatings derived from aqueous dispersions of zein.
Goldie Robert S. (Cambridge GB2) Malkowska Sandra T. A. (Cambridge GB2) Leslie Stewart T. (Cambridge GB2) Miller Ronald B. (Basel CHX), Controlled release dihydrocodeine composition.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
Oshlack Benjamin (New York NY) Pedi ; Jr. Frank (Yorktown Heights NY) Chasin Mark (Manalapan NJ), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
Goldie Robert S. (Comberton GB2) Malkowska Sandra T. A. (Landbeach GB2) Leslie Stewart T. (Cambridge GB2) Miller Ronald B. (Basel CHX), Controlled release hydromorphone composition.
Goldie Robert S. (Comberton GBX) Malkowska Sandra T. A. (Landbeach GBX) Leslie Stewart T. (Cambridge GBX) Miller Ronald B. (Basel CHX), Controlled release hydromorphone composition.
Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Minogue John J. (Mount Vernon NY) Kaiko Robert F. (Weston CT), Controlled release oxycodone compositions.
Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Minogue John J. (Mount Vernon NY) Kaiko Robert F. (Weston CT), Controlled release oxycodone compositions.
Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Minogue John Joseph (Mount Vernon NY) Kaiko Robert Francis (Weston CT), Controlled release oxycodone compositions.
Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Controlled-release formulations coated with aqueous dispersions of ethylcellulose.
Prasit Petpiboon (Kirkland CAX) Guay Daniel (Iie Perrot CAX) Wang Zhaoyin (Pierrefonds CAX) Leger Serge (Dollar des Ormeaux CAX) Therien Michel (Laval CAX), Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2.
Bjork, Anders K. K.; Olsson, Knut G.; Abramo, Aina L.; Christensson, Erik G., Diphenylbutyl-piperazinecarboxamides in pharmaceutical compositions and methods.
Sawada, Toyohiro; Sako, Kazuhiro; Yoshioka, Tatsunobu; Watanabe, Shunsuke, Drug delivery system for averting pharmacokinetic drug interaction and method thereof.
Han, Chien-Hsuan; Hou, Sui Yuen Eddie; Reid, Monica L., Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic.
Mayer, David J.; Price, Donald D.; Mao, Jianren; Lyle, John W., Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance.
Mayer David J. (Richmond VA) Price Donald D. (Richmond VA) Mao Jianren (Richmond VA) Lyle John W. (Belmar NJ), Inhibiting the development of tolerance to and/or dependence on an addictive substance.
Crain Stanley M. (Leonia NJ) Shen Ke-fei (Flushing NY), Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other o.
Sackler Richard S. (Greenwich CT) Kaiko Robert F. (Weston CT) Goldenheim Paul (Wilton CT), Method of treating pain by administering 24 hour oral opioid formulations.
Sackler Richard (Greenwich CT) Goldenheim Paul (Wilton CT) Kaiko Robert (Weston CT), Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasm.
Colombo Paolo (Milan ITX) Cardona Antonio C. (Milan ITX) Pifferi Giorgio (Milan ITX), Multilayer matrix systems for the controlled release of active principles.
Lau Cheuk Kun (Ile Bizard CAX) Black Cameron (Pointe Claire CAX) Guay Daniel (Ile Perrot CAX) Gauthier Jacques-Yves (Laval CAX) LeBlanc Yves (Kirkland CAX) Roy Patrick (Dollard des Ormeaux CAX) Ducha, N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors.
Lau Cheuk K. (Ile Bizard CAX) Black Cameron (Pointe Claire CAX) Belley Michel (Pierrefonds CAX), N-benzyl-3-indoleacetic acids as antiinflammatory drugs.
Lau Cheuk K. (Ile Bizard CAX) Black Cameron (Pointe Claire CAX) Guay Daniel (Ile Perrot CAX) Gauthier Jacques Y. (Laval CAX) LeBlanc Yves (Kirkland CAX) Roy Patrick (Dollard des Ormeaux CAX) Ducharme, N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors.
Houn Simon Hsia ; David Fan, Nutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates.
Shaw Irving F. (East Rockaway NY) Berk Jerome (New Rochelle NY), Orally administered drug composition for therapy in the treatment of narcotic drug addiction.
Wong Patrick S. L. (Hayward CA) Barclay Brian L. (Sunnyvale CA) Deters Joseph C. (Mt. View CA) Theeuwes Felix (Los Altos CA), Osmotic device for administering certain drugs.
Wong Patrick S. L. (Hayward CA) Barclay Brian (Sunnyvale CA) Deters Joseph C. (Mt. View CA) Theeuwes Felix (Los Altos CA), Osmotic device with dual thermodynamic activity.
Guillaumet Grald (Orleans FRX) Flouzat Christine (Clermont Ferrand FRX) Devissaguet Michelle (Neuilly sur Seine FRX) Renard Pierre (Versailles FRX) Caignard Daniel H. (Paris FRX) Adam Grard (le Mesni, Oxazolopyridine compounds, compositions and use.
Fukunaga Atsuo F. (5411 Littlebow Rd. Rancho Palos Verdes CA 90274) Funuknaga Alex S. (5411 Littlebow Rd. Rancho Palos Verdes CA 90274), Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine.
Batt Douglas G. (Wilmington DE) Pinto Donald J. P. (Newark DE) Orwat Michael J. (Wilmington DE) Petraitis Joseph J. (Glenmoore PA) Pitts William J. (Newark DE), Prostaglandin synthase inhibitors.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Stabilized controlled release formulations having acrylic polymer coating.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
Oshlack Benjamin (New York NY) Pedi ; Jr. Frank (Yorktown Heights NY) Chasin Mark (Manalapan NJ), Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
Heafield Joanne,GB2 ; Knott Trevor John,GB2 ; Leslie Stewart Thomas,GB2 ; Malkowska Sandra Therese Antoinette,GB2 ; Miller Ronald Brown,CHX ; Prater Derek Allan,GB2 ; Smith Kevin John,GB2, Sustained release compositions of morphine and a method of preparing pharmaceutical compositions.
Schor Joseph M. (Locust Valley NY) Nigalaye Ashok (Jackson Heights NY) Gaylord Norman G. (New Providence NJ), Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose.
Staniforth John N.,GB2 ; Sherwood Bob E. ; Hunter Edward A., Sustained-release formulations utilizing pharmaceutical excipient having improved compressibility.
Chien Yie W. (North Brunswick NJ) Chiang Chin-Chih (Piscataway NJ) Tojo Kabuji (Highland Park NJ), Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration.
Gale Robert M. (Los Altos CA) Goetz Victor (Palo Alto CA) Lee Eun S. (Redwood City CA) Taskovich Lina T. (Palo Alto CA) Yum Su I. (Los Altos CA), Transdermal administration of fentanyl and device therefor.
Hille Thomas (Neuwied DEX) Deurer Lothar (Koblenz DEX) Hoffmann Hans-Rainer (Neuwied DEX), Transdermal therapeutic system comprising as active component buprenorphine.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.